Capping is the addition of a protective chemical “cap” to the front end of a messenger RNA molecule, and it happens almost immediately after transcription begins. When RNA polymerase II starts building an mRNA strand from a DNA template, capping enzymes attach a modified guanosine nucleotide to the molecule’s leading tip once the transcript is only about 25 to 30 nucleotides long. This makes capping the very first modification an mRNA receives, occurring before splicing or any other processing step.
What the Cap Actually Is
The 5′ cap is a guanosine nucleotide that has been methylated (had a small chemical group added) at a specific position. What makes it unusual is how it’s attached: instead of the normal head-to-tail linkage between nucleotides, the cap guanosine is connected in a reversed orientation through a triphosphate bridge. Think of it as a nucleotide glued on backwards. This reversed linkage is what makes the cap resistant to the enzymes that would otherwise chew up the RNA from its exposed end.
The simplest version, called Cap 0, has just the single methyl group on the guanosine. In higher organisms, additional methyl groups are added to the first and sometimes second nucleotides of the original RNA chain, creating Cap 1 and Cap 2 structures. These extra modifications matter because the cell’s immune sensors use them to distinguish its own mRNA from foreign RNA. An mRNA missing the right cap pattern can trigger an immune response.
How the Cap Gets Built in Three Steps
Building the cap requires three enzymes working in sequence on the fresh end of the growing mRNA strand:
- Step 1: The first enzyme clips off one phosphate group from the three phosphates naturally present at the mRNA’s leading end, leaving two phosphates behind.
- Step 2: The second enzyme attaches a GMP nucleotide (taken from a GTP molecule) to those two remaining phosphates, forming the unusual reversed triphosphate bridge.
- Step 3: The third enzyme adds a methyl group to the newly attached guanosine, completing the Cap 0 structure.
These three reactions happen in strict order. Each enzyme’s product becomes the next enzyme’s starting material, so skipping a step isn’t possible.
Why Capping Happens So Early
Capping is tightly coordinated with the start of transcription through a direct physical connection to RNA polymerase II, the enzyme that builds the mRNA. As the polymerase begins transcribing, a long tail on the polymerase (called the C-terminal domain) gets chemically tagged with phosphate groups. The capping enzymes recognize and bind to this phosphorylated tail, essentially hitching a ride on the transcription machinery. This is why capping happens when the transcript is still tiny, just 25 to 30 nucleotides long. The polymerase’s own activation signal doubles as a recruitment signal for the capping enzymes.
Because this phosphorylation only happens on RNA polymerase II, capping is specific to the transcripts that polymerase produces. Other types of RNA, like ribosomal RNA or transfer RNA made by different polymerases, don’t get capped.
What the Cap Does for the mRNA
The cap serves several critical functions throughout the mRNA’s life. It protects the molecule from degradation, helps it get processed and exported from the nucleus, enables it to be translated into protein, and signals to the immune system that the RNA belongs to the cell rather than to a virus.
Once the cap is in place, a two-protein complex called the cap-binding complex (CBC) latches onto it. Neither protein in this pair can grip the cap well on its own. The larger protein causes a shape change in the smaller one, and together they bind the cap tightly. This complex then acts as a landing pad, recruiting the machinery needed for splicing (removing non-coding segments from the mRNA), for exporting the finished mRNA through the nuclear pore into the cytoplasm, and even for driving the very first round of protein translation.
The CBC also protects the mRNA indirectly by blocking an enzyme that would otherwise start removing the poly(A) tail at the other end of the molecule. Since tail removal is the first step in mRNA destruction, the cap effectively stabilizes the entire transcript from both ends.
Later, once the mRNA reaches the cytoplasm and begins routine translation, a different cap-binding protein takes over. This protein is part of the translation initiation complex that recruits ribosomes to the mRNA, making the cap essential for efficient protein production.
How Viruses Handle Capping
Because cells depend on the cap to identify legitimate mRNA, viruses face a problem: their RNA needs a cap to be translated by the host cell’s machinery, but they don’t always have the enzymes to make one. Different virus families have evolved creative workarounds.
One striking strategy is “cap snatching,” used by influenza and other negative-sense RNA viruses including those in the Arenaviridae and Bunyaviridae families. The virus’s polymerase complex grabs a host mRNA, recognizes its cap, and snips off a short capped fragment. That stolen fragment then serves as a primer to start copying the viral genome. Influenza does this with a three-protein polymerase complex: one protein binds the host cap, another cuts the RNA a short distance from the cap, and the fragment is used to kickstart viral RNA synthesis.
Other viruses skip the cap entirely. Picornaviruses, which include poliovirus and rhinovirus, attach a small protein to the front of their RNA instead of a cap. Some viruses in the Hepacivirus genus (including hepatitis C) leave their RNA’s leading end completely unprotected and rely on other strategies to evade immune detection and drive translation.
Capping in mRNA Vaccines
When scientists manufacture mRNA for vaccines or therapies, they need to add a cap to the synthetic mRNA or it won’t work inside cells. Two main approaches exist. The traditional method uses a two-step enzymatic reaction after the mRNA is made, essentially mimicking the cell’s own capping process in a test tube. The newer approach, called co-transcriptional capping, builds the cap into the mRNA as it’s being synthesized. Co-transcriptional methods reduce the number of reaction steps and enzymes needed. One widely used co-transcriptional system achieves about 94% capping efficiency while producing Cap 1 structures, a significant improvement over earlier cap analogs that produced Cap 0 structures at lower efficiency and yield. Getting the cap structure right is important: a Cap 1 structure (with the extra methylation) helps the synthetic mRNA avoid triggering the recipient’s innate immune defenses, the same self-versus-foreign detection system that cells use naturally.